HEMO: Hemogenyx Pharmaceuticals Plc - Summary | Jitta

Hemogenyx Pharmaceuticals Plc

LON:HEMO

Price
£7.71
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (3)
Recent Business Performance (14)
Financial Strength (22)
Return to Shareholders (3)
Competitive Advantage (8)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 3.64% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.15
100.83%
3.28
141.83%
Biotechnology
2.08
100.00%
1.46
100.00%
2.46
100.00%
COMPANY DESCRIPTION
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.